We observed that the percentage of PLOD2 + SAA1 + tumor cells with high MECRGS scores (Fig. 8G-J), as well as the expression of immune checkpoints such as NECTIN2 and CD47, increased in patients who exhibited a partial response (PR) to immunotherapy (Fig. 8K). This evidence concerns the gene CD47 and neoplasm.